Page 3 - Mark Neumann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Privium Fund Management B.V. boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 12.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,650 shares of the biopharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has earned a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the […]

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the […]

Orion Portfolio Solutions LLC lowered its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 3.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 27,298 shares of the biopharmaceutical company’s stock after selling 1,061 shares during the period. Orion Portfolio Solutions LLC’s holdings […]

TD Cowen started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $75.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also commented on ITCI. Needham & Company LLC upped their […]